Phase 2 trial of ponatinib for the treatment of chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) - MPR
Links shared publicly online about this topic.
- 876total visits
Phase 2 trial of ponatinib for the treatment of chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) - MPR
empr.com —
View full resource at empr.com
Tags: Leukemia, Chronic Myelogenous Leukemia, Phase 2 Clinical Trial, Clinical Trial, News
Most Recently Shared on September 13, 2010 at 5:01 pm By:
MPR News: Phase 2 trial of ponatinib for the treatment of chronic myeloid leukemia (CML) and Philadelphia positive... http://bit.ly/aUGg7V
ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia
news-medical.net — “ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).” View full resource at news-medical.net
Most Recently Shared on September 13, 2010 at 1:26 pm By:
News-Medical.Net Health News and Oncology
Oncology News: ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia: ARIAD Pha... http://bit.ly/bOZm54
Advertisement
